Use access key #2 to skip to page content.
$19.72 -1.38 (-6.54%)
10/10/2008 4:00 PM

The Medicines Company (MDCO)

CAPS Rating:
**

A pharmaceutical company provides innovative, cost effective acute care hospital products to the worldwide hospital marketplace.

X

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating MDCO

Add Stock to Watchlist

What the Community Thinks

Total Members

54 Outperforms
13 Underperforms
 

All-Stars

13 Outperforms
5 Underperforms
 

Wall Street

4 Outperforms
1 Underperforms
 

Members bullish on MDCO are also bullish on:

Members bearish on MDCO are also bearish on:

Ticker Tags

Drug Manufacturers - Other (105), Small Cap (1922)
Suggest a tag

The Medicines Company At A Glance

Current Price: $19.72
Last Trade Time: 10/10/2008 4:00 PM
Open: $20.63
Previous Close: $21.10
Daily Range: $18.38 - $21.24
52-Week Range: $16.38 - $28.00
Volume: 1,504,287
Market Cap: $1.10B
P/E Ratio: 39.55
Compare Our Special Broker Offers!

Stock Trends

MDCO VS S&P 500 (SPY)

MDCO 12 month chart vs. S&P

News & Discussion Boards

Other News Headlines for MDCO

More Headlines...

Top Bull Pitch

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches below!

Top Bear Pitch

Recs

1

The Medicines Company (MDCO)

Avatar agard43 (< 20) Submitted: 3/22/07 10:31 PM

TheStreet.com: "There still seems to be a lot of hope built into the stock price. As Morgan Stanley analyst Stephen Herr wrote this week, "if the patent life is not extended, this stock looks broadly overvalued."

Replies: 0 | Reply | Permalink

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 9 :   1 2 Next »

Show Pitch Replies

Recs

0

 (MDCO)

Avatar zzlangerhans (98.66) Submitted: 6/30/08 2:58 PM : Underperform Start Price: $20.03 MDCO Score: -29.47

Angiomax revenues are increasing in elective cardiac catheterization, but the rejection by the FDA for use in acute coronary syndrome was a significant blow. Furhtermore, Angiomax is scheduled to come off patent in 2010 thanks to a completely boneheaded miss of a patent extension deadline. Lobbying efforts for legislation to remediate the error will likely be unsuccessful. The company is being very cagey about the NDA for Cleviprex, only belatedly revealing an FDA request for more data with resultant PDUFA delay. Catalysts could be positive as well as negative, but with a share price drifting over 20 I feel that negatives now outweigh positives.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (MDCO)

Avatar escarzamd (36.09) Submitted: 5/31/08 2:26 PM : Outperform Start Price: $18.25 MDCO Score: 44.76

Hearing good things from cardiologists about Angiomax. recent support from journals. Could be a combo w/BMY for cath patients. No debt on board, so if this drug hits.......the stock could go out of the yard.

Report this Post Replies: 1 | Reply | Permalink

Recs

0

 (MDCO)

Avatar popsstocs (< 20) Submitted: 9/08/07 3:39 PM : Outperform Start Price: $16.47 MDCO Score: 59.33

I have made some good profits off this CO.I guess it makes all that money from selling all those expensive medications,but what ever,It does me good and I played it again,and its already on its way to do ole pops right again.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (MDCO)

Avatar StocksdatROCK (35.66) Submitted: 9/04/07 7:53 PM : Outperform Start Price: $16.81 MDCO Score: 57.59

Has the worlds favorite item and to many customers

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (MDCO)

Avatar almond9090 (59.23) Submitted: 8/17/07 5:43 AM : Outperform Start Price: $16.50 MDCO Score: 58.69

Consistent steady growth with well-established product should slightly outperform the market.

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 9 :   1 2 Next »

Wall Street

Results 1 - 5 of 5  

picks per page. CHANGE

Top
Pick		Member NameMember RatingStart
Date		CallTime FrameStart
Price		Stock
Gain		S&P
Gain		ScorePitch
TrackCitigroup < 20 02/14/08 Outperform NS $21.23-7.11%-35.38%+28.27
TrackUBS 83.70 10/02/07 Outperform NS $19.50+1.13%-42.76%+43.89
TrackJMP 24.52 04/30/07 Outperform NS $23.13-14.74%-40.86%+26.12
TrackFirstAlbany 82.37 10/26/06 Outperform NS $24.65-20.00%-36.20%+16.20
TrackJimCramer 81.55 03/13/06 Underperform 3W $21.40-7.85%-31.45%-23.60

Results 1 - 5 of 5  

X

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners